References
1. Christina Fotopoulou, Jalid Sehouli, Giovanni Aletti, Philipp Harter, Sven Mahner, Denis Querleu, Luis Chiva, Hani Gabra, Nicoletta Colombo, Andreas du Bois. Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. J Clin Oncol. 2017;35(6):587-590. doi: 10.1200/JCO.2016.71.0723. Epub 2017 Jan 9.
2. Morrison J. Neoadjuvant chemotherapy for ovarian cancer: Avoiding ’needless hurt’? BJOG. 2023 Jul 30. doi: 10.1111/1471-0528.17627.
3. Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, Guyon F, Greggi S, Mosgaard BJ, Reinthaller A, Hilpert F, Schade-Brittinger C, Chi DS, Mahner S. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331.
4. Fotopoulou C, Concin N, Planchamp F, Morice P, Vergote I, du Bois A, Querleu D.
Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer. 2020 Apr;30(4):436-440. doi: 10.1136/ijgc-2020-001248. Epub 2020 Feb 20.)
5. J Alejandro Rauh-Hain, Alexander Melamed, Alexi Wright, Allison Gockley, Joel T Clemmer, John O Schorge, Marcela G Del Carmen, Nancy L Keating. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol 2017;3(1):76-82. doi: 10.1001/jamaoncol.2016.4411.
6. Harter P, Mouret-Reynier MA, Pignata S, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol 2022; 164(2): 254-64.